Skip to main content
Erschienen in: Journal of Neurology 8/2020

04.05.2020 | Original Communication

Familial Creutzfeldt–Jakob disease homozygous to the E200K mutation: clinical characteristics and disease course

verfasst von: Zeev Nitsan, Oren S. Cohen, Joab Chapman, Esther Kahana, Amos D. Korczyn, Shmuel Appel, Michael Osherov, Hanna Rosenmann, Ron Milo

Erschienen in: Journal of Neurology | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Abstract

Objective

To characterize the demographic, clinical features and disease course of familial Creutzfeldt–Jakob disease (fCJD) patients homozygous to the E200K mutation.

Methods

The Israeli National CJD Database was screened for patients homozygous to the E200K mutation. Patients' demographic data, clinical presentation and neurological findings, tau protein levels in the cerebrospinal fluid (CSF) and EEG, were assessed.

Results

Ten homozygous E200K patients were identified (80% males). Average age of onset was 47.5 ± 6.1 years (range 40–56) and the average age of death was 49.3 ± 7. 7 years (range 42–63) with average disease duration of 27.7 ± 9.7 months (range 2–97). Initial clinical presentation included behavioral change in 4/10 patients, cognitive decline in 3/10 patients and focal neurological deficits in 2/10 patients. Throughout the disease course, the clinical signs in descending order of prevalence included cerebellar (70%), brainstem (60%), extrapyramidal (50%), pyramidal (50%), frontal lobe signs (30%), and disturbances of ocular motility (30%) Compared to the 228 heterozygous E200K fCJD patients, the 10 homozygous patients were significantly younger at disease onset (47.5 vs 59.7 years, p < 0.001), had a longer disease duration (27.7 vs 8.5 months, p < 0.001) and presented more frequently with behavioral changes as initial manifestation (4/10 vs. 34/228, p = 0.05).

Conclusions

Homozygous E200K fCJD patients are characterized by a relatively younger age of onset and longer disease duration. Behavioral changes as a presenting symptom were more common in homozygous patients and cerebellar dysfunction was the most common neurological manifestation throughout the disease course.
Literatur
1.
2.
Zurück zum Zitat Knight RS, Will RG (2004) Prion diseases. J Neurol Neurosurg Psychiatry 75(Suppl 1):i36–42CrossRef Knight RS, Will RG (2004) Prion diseases. J Neurol Neurosurg Psychiatry 75(Suppl 1):i36–42CrossRef
3.
Zurück zum Zitat Korczyn AD, Chapman J, Goldfarb LG, Brown P, Gajdusek DC (1991) A mutation in the prion protein gene in Creutzfeldt–Jakob disease in Jewish patients of Libyan, Greek, and Tunisian origin. Ann N Y Acad Sci 640:171–176CrossRef Korczyn AD, Chapman J, Goldfarb LG, Brown P, Gajdusek DC (1991) A mutation in the prion protein gene in Creutzfeldt–Jakob disease in Jewish patients of Libyan, Greek, and Tunisian origin. Ann N Y Acad Sci 640:171–176CrossRef
4.
Zurück zum Zitat Kahana E, Alter M, Braham J, Sofer D (1974) Creutzfeldt–jakob disease: focus among Libyan Jews in Israel. Science 183:90–91CrossRef Kahana E, Alter M, Braham J, Sofer D (1974) Creutzfeldt–jakob disease: focus among Libyan Jews in Israel. Science 183:90–91CrossRef
5.
Zurück zum Zitat Simon ES, Kahana E, Chapman J, Treves TA, Gabizon R, Rosenmann H et al (2000) Creutzfeldt–Jakob disease profile in patients homozygous for the PRNP E200K mutation. Ann Neurol 47:257–260CrossRef Simon ES, Kahana E, Chapman J, Treves TA, Gabizon R, Rosenmann H et al (2000) Creutzfeldt–Jakob disease profile in patients homozygous for the PRNP E200K mutation. Ann Neurol 47:257–260CrossRef
6.
Zurück zum Zitat Zlotogora J (1997) Dominance and homozygosity. Am J Med Genet 68:412–416CrossRef Zlotogora J (1997) Dominance and homozygosity. Am J Med Genet 68:412–416CrossRef
7.
Zurück zum Zitat Farnier M, Bruckert E (2012) Severe familial hypercholesterolaemia: current and future management. Arch Cardiovasc Dis 105:656–665CrossRef Farnier M, Bruckert E (2012) Severe familial hypercholesterolaemia: current and future management. Arch Cardiovasc Dis 105:656–665CrossRef
8.
Zurück zum Zitat Sturtz FG, Latour P, Mocquard Y, Cruz S, Fenoll B, LeFur JM et al (1997) Clinical and electrophysiological phenotype of a homozygously duplicated Charcot–Marie-Tooth (type 1A) disease. Eur Neurol 38:26–30PubMed Sturtz FG, Latour P, Mocquard Y, Cruz S, Fenoll B, LeFur JM et al (1997) Clinical and electrophysiological phenotype of a homozygously duplicated Charcot–Marie-Tooth (type 1A) disease. Eur Neurol 38:26–30PubMed
9.
Zurück zum Zitat Sobue G, Doyu M, Nakao N, Shimada N, Mitsuma T, Maruyama H et al (1996) Homozygosity for Machado–Joseph disease gene enhances phenotypic severity. J Neurol Neurosurg Psychiatry 60:354–356CrossRef Sobue G, Doyu M, Nakao N, Shimada N, Mitsuma T, Maruyama H et al (1996) Homozygosity for Machado–Joseph disease gene enhances phenotypic severity. J Neurol Neurosurg Psychiatry 60:354–356CrossRef
10.
Zurück zum Zitat Cubo E, Martinez-Horta SI, Santalo FS, Descalls AM, Calvo S, Gil-Polo C et al (2019) Clinical manifestations of homozygote allele carriers in Huntington disease. Neurology 92:e2101–e2108PubMed Cubo E, Martinez-Horta SI, Santalo FS, Descalls AM, Calvo S, Gil-Polo C et al (2019) Clinical manifestations of homozygote allele carriers in Huntington disease. Neurology 92:e2101–e2108PubMed
11.
Zurück zum Zitat WHO (1998) Global surveillance, diagnosis and therapy of human transmissible spongiform encephalopathies: Report of the WHO consultation. In: World Health Organization: emerging and other communicable diseases, surveillance and control, Geneva, pp 9–11 WHO (1998) Global surveillance, diagnosis and therapy of human transmissible spongiform encephalopathies: Report of the WHO consultation. In: World Health Organization: emerging and other communicable diseases, surveillance and control, Geneva, pp 9–11
12.
Zurück zum Zitat Zilber N, Kahana E, Abraham M (1991) The Libyan Creutzfeldt–Jakob disease focus in Israel: an epidemiologic evaluation. Neurology 41:1385–1389CrossRef Zilber N, Kahana E, Abraham M (1991) The Libyan Creutzfeldt–Jakob disease focus in Israel: an epidemiologic evaluation. Neurology 41:1385–1389CrossRef
13.
Zurück zum Zitat Cohen OS, Prohovnik I, Korczyn AD, Ephraty L, Nitsan Z, Tsabari R et al (2011) The Creutzfeldt–Jakob disease (CJD) neurological status scale: a new tool for evaluation of disease severity and progression. Acta Neurol Scand 124:368–374CrossRef Cohen OS, Prohovnik I, Korczyn AD, Ephraty L, Nitsan Z, Tsabari R et al (2011) The Creutzfeldt–Jakob disease (CJD) neurological status scale: a new tool for evaluation of disease severity and progression. Acta Neurol Scand 124:368–374CrossRef
14.
Zurück zum Zitat Spudich S, Mastrianni JA, Wrensch M, Gabizon R, Meiner Z, Kahana I et al (1995) Complete penetrance of Creutzfeldt–Jakob disease in Libyan Jews carrying the E200K mutation in the prion protein gene. Mol Med 1:607–613CrossRef Spudich S, Mastrianni JA, Wrensch M, Gabizon R, Meiner Z, Kahana I et al (1995) Complete penetrance of Creutzfeldt–Jakob disease in Libyan Jews carrying the E200K mutation in the prion protein gene. Mol Med 1:607–613CrossRef
15.
Zurück zum Zitat Chapman J, Ben-Israel J, Goldhammer Y, Korczyn AD (1994) The risk of developing Creutzfeldt–Jakob disease in subjects with the PRNP gene codon 200 point mutation. Neurology 44:1683–1686CrossRef Chapman J, Ben-Israel J, Goldhammer Y, Korczyn AD (1994) The risk of developing Creutzfeldt–Jakob disease in subjects with the PRNP gene codon 200 point mutation. Neurology 44:1683–1686CrossRef
16.
Zurück zum Zitat Corato M, Cereda C, Cova E, Ferrarese C, Ceroni M (2006) Young-onset CJD: age and disease phenotype in variant and sporadic forms. Funct Neurol 21:211–215PubMed Corato M, Cereda C, Cova E, Ferrarese C, Ceroni M (2006) Young-onset CJD: age and disease phenotype in variant and sporadic forms. Funct Neurol 21:211–215PubMed
17.
Zurück zum Zitat Boesenberg C, Schulz-Schaeffer WJ, Meissner B et al (2005) Clinical course in young patients with sporadic Creutzfeldt–Jakob disease. Ann Neurol 58:533–554CrossRef Boesenberg C, Schulz-Schaeffer WJ, Meissner B et al (2005) Clinical course in young patients with sporadic Creutzfeldt–Jakob disease. Ann Neurol 58:533–554CrossRef
Metadaten
Titel
Familial Creutzfeldt–Jakob disease homozygous to the E200K mutation: clinical characteristics and disease course
verfasst von
Zeev Nitsan
Oren S. Cohen
Joab Chapman
Esther Kahana
Amos D. Korczyn
Shmuel Appel
Michael Osherov
Hanna Rosenmann
Ron Milo
Publikationsdatum
04.05.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 8/2020
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-020-09826-z

Weitere Artikel der Ausgabe 8/2020

Journal of Neurology 8/2020 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.